Telo Genomics Completes Final Tranche of Oversubscribed Private Placement
Toronto, Ontario--(Newsfile Corp. - July 5, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces that it has closed the second and final tranche of its previously announced non-brokered private placement ("Offering") of units (the "Units") and issued an additional 390,000 Units for gross proceeds of $195,000. The originally announced Offering was oversubscribed and along with the first tranche of the Offering, the Company has now raised $2,287,750. Each Unit issued...
2021-07-05 8:45 AM EDT
Telo Genomics Completes First Tranche of Oversubscribed Private Placement
Toronto, Ontario--(Newsfile Corp. - July 2, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") announces that it has closed the first tranche of its previously announced non-brokered private placement ("Offering") of units (the "Units"). The Company issued a total of 4,185,500 Units at a price of $0.50 per Unit for gross proceeds of $2,092,750 under the first tranche of the Offering. Each Unit issued consisted of one common share of the Company (a "Common Share") and one-half...
2021-07-02 8:45 AM EDT
Telo Genomics Announces Private Placement of Units
Toronto, Ontario--(Newsfile Corp. - June 18, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce a non-brokered private placement of units ("Units") at a price of $0.50 per Unit for gross proceeds of $1,500,000 (the "Offering"). Each Unit will consist of one common share of the Company (a "Common Share") and one-half of one non-transferable common share purchase warrant (each whole warrant, a "Warrant"). Each Warrant will entitle the holder to acquire one...
2021-06-18 10:00 AM EDT
Telo Genomics Announces Co-Authored Publication of a Prospective 5-year Multiple Myeloma Study - Successfully Identifying High Risk versus Low Risk Smoldering Myeloma Patients
Toronto, Ontario--(Newsfile Corp. - April 29, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce that it has co-authored a publication demonstrating TELO's ability to identify high risk versus low-risk smoldering myeloma patients in a large longitudinal prospective multiple myeloma clinical study including 214 patients. The study was recently published in the Scientific Journal titled "Cancers". "This study confirms the potential of TeloView® technology...
2021-04-29 8:30 AM EDT
Telo Genomics Announces AGM Voting Results and Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 24, 2021) - Telo Genomics Corp. (TSXV: TELO) (the "Company" or "TELO") is pleased to announce the results of its recent annual general shareholders meeting (the AGM) held on March 04, 2021 in Toronto, ON. The Company is also pleased to provide a corporate update, including an update on its lead clinical development program. AGM Results TELO wishes to announce the voting results from the AGM held on March 04, 2021. A total of 5,161,568 shares...
2021-03-24 9:15 AM EDT
IIROC Trade Resumption - 3D SIGNATURES INC.
Vancouver, British Columbia--(Newsfile Corp. - September 12, 2016) - Trading resumes in: Company: 3D SIGNATURES INC.
2016-09-12 4:17 PM EDT
IIROC Trade Halt - Plicit Capital Corp.
Vancouver, British Columbia--(Newsfile Corp. - December 2, 2015) - The following issues have been halted by IIROC: Company:
2015-12-02 8:05 AM EST
IIROC Trade Halt - Plicit Capital Corp.
Vancouver, British Columbia--(Newsfile Corp. - January 17, 2014) - The following issues have been halted by IIROC: Company:
2014-01-17 1:57 PM EST